Etrolizumab

(Synonyms: rhuMAb Beta7; RG7413; PRO145223)
2 Cited Publications
Customer Review

Based on 2 publication(s) in Google Scholar

Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD).

For research use only. We do not sell to patients.

  • Purity: 99.56%
  • CAS No.: 1044758-60-2
  • Molecular Weight:144.3 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00